Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.10) per share which beat the an

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected

BURLINGTON, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, whi

The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technicall

BURLINGTON, Mass. , May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a c

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and firs

Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) was the recipient of a large growth in s

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remai

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company

Minerva Neurosciences (NASDAQ: NERV) provided an update on its development program for roluperidone,

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negativ

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a c

UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are

Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will a

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings f

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesda

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders

Gainers

  On Friday, 153 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week

    During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid

Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company

  Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings

  Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Friday

Stocks Which Set New 52-Week High Yesterday, September 13th